The results of ML17032 confirmed that patients receiving the Xeloda/cisplatin combination lived at least as long without the cancer progressing as those treated with 5-FU/cisplatin.

• ML17032研究证实接受希罗达+顺铂联合疗法的患者癌症无进展生存期至少与那些接受5-FU+顺铂联合疗法的患者一样长。